The selective action of U-74389G on ovaries among rat female internal genitalia

Aim. This study reviewed four studies referenced after U-74389G (L) administration. Three studies concerned his­to­lo­gic variables for rat uteri, fallopian tubes and ova­ries, res­pec­tively. Each organ was examined for four cer­tain his­to­lo­gic variables, such as edema, karyorrhexis, con­ges­tion and inflammation (EKCI), in an induced ischemia re­per­fu­sion experiment. Furthermore, cytokine (TNF-α) and oxi­dant marker malondialdehyde (MDA) were calculated along with ovaries, whereas the associated fourth study con­cerned the serum spectrum. Materials and method. The two main experimental timepoints at which the EKCI va­ria­bles of organs were examined, as well as the TNF-α and MDA scores and serum values were evaluated were the 60th re­per­fu­sion minute for two groups (A and C) and the 120th re­per­fu­sion minute for the other two groups (B and D). In par­ti­cu­lar, groups A and B were processed without drugs, where­as groups C and D were processed after the ad­mi­nis­tra­tion of U-74389G. Results. The preliminary studies showed that U-74389G has a nonsignificant deteriorating ef­fect on uteri pathology within the “lesion alteration-free” score by 0.0758471 (0.1464624-0.2981566; p=0.4940), and also a nonsignificant deteriorating effect on fallopian tubes pathology within the “lesion alteration-free” score by 0.0073429 (0.0475001-0.0621858; p=0.7878), but a sig­ni­fi­cant recession effect on ovarian pathology within the “le­sion alteration-free” score by 0.1772727 (-0.3208232 – -0.0337223; p=0.0169). Valuable outcomes confirmed the above from the calculations performed for TNF-α and MDA scores, and the overall metabolic sign of the fourth study. Conclusions. U-74389G administration was significantly active only for ovarian pathology (p=0.0169), in accordance with the reduced TNF-α levels by 4.69% (±8.40%; p=0.5749), the significantly reduced MDA levels by 9.85% (±2.66%; p=0.0005), and the overall me­ta­bo­lic vector of the agent.